Member Info for Retireby40

The deal is massive and clearly very complex. I stand by my point though, it doesn’t reflect well on GB to state on Twitter (a week ago) all is on track. Anyway, let’s see what midday brings.

We knew the scope of the China Resources deal had expanded hence the delay from end of June to early Q1 but for GB to say on Twitter a week ago all is on track is BS. Now we are looking at Q4 so kicking off by end of Sept not happening and be would have known that last week. It’s unprofessional and he doesn’t help himself.

No wonder the marker has reacted negatively.

That said the deal I’m sure will be transformational, GB just needs to sort his social media bluster out as it reflects poorly.

It’s 28p to buy, chill out lad. We’ll also need nearer to £15m than £10m to achieve 100% growth (I expect we will and could have an upgrade sooner rather than later).

Have a good weekend all.

In fact I’m not sure many PLCs do an early H1 update, out and about so can’t really check.

Morning PaulCon, agreed but give it’s in July we could also have a H1 trading update, many PLCs do so before the unaudited interim report is released in Sept. anyway, am looking forward to the update regardless. Hopefully an RNS Monday morning.

On a plus side there’s no pump and dump last time and not even a hint of FOMO so any good news should see a sustained uplift. Hopefully it’s sustained as that’s been the issue. Hopefully we get some genuine detail and not woolly jam tomorrow.

Anterior nasal is non-invasive and more reliable than an inside cheek sample given what we eat and drink. That said the test looks very impressive. No CE mark and did it pass PD or like us has gone its own route?

The EU is also tightening its regulations and will update its lost with CV every 8 weeks. Next one due mid-August. A sensitivity of 90% for Ct<25 needed and we will
Show 100%. I imagine quite a few LFTs will fall short. Interested to see the list next month.

https://mobile.twitter.com/BigBiteNow/status/1417025291755663364

*rumoured to be at a site in Spain

Smith seemingly does stuff by the book and the CV was carried out at a site in Spain. Because they didn’t state it was done independently doesn’t mean it wasn’t. You’ve stated it as a fact so you are making it up and you’re making assumptions.

Given the Elisa performance versus Abcam’s it should be no surprise our LFT is the best. Abcam also selling that test and have not disputed our findings (they’re also a PLC).

Anyway, this is boring but I stand by what I said. You’re stating assumptions as facts. Bore off.

Let’s remember our Elisa test is 500 x more sensitive than Abcam’s. The power of the Affimer.

So you’re assuming it wasn’t independent whereas you stated it as a fact and several times. Clear agenda. PD a joke as is MHRA. Hopefully we get some licensing deals or OEMs in the EU and beyond. Testing and accurate LFTs will be around for years. Frustrating at the mo but there is no LFT with a better performance then Avacta’s. Frustrated with the share price but am as confident as I have been. AVA6000 dosing in the coming weeks.

Deeks is clear whe he says they use saliva at PD rather than the buffer solution provided.

https://twitter.com/deeksj/status/1416888524243148802?s=21

They still aren’t even allowing the manufacturers instructions for each test at Porton Down Irene - they are sticking saliva on every test rather than assessing them with the provided buffer solution. They fail to get tests to work where others have succeeded around the globe.

Ndn how do you know the CV wasn’t carried out independently at the one site in Europe (rumoured to be Spain)? You’re making it up again.

All good thanks mate and hope you are too. Still holding here for my sins!

If there isn’t a material RNS before the AGM on Monday I suspect this will fall further. I know markets are down all over but this fall below placing isn’t good. Gerry said China Resources deal to be signed in early Q3 so that’s July. I just hope it’s before the AGM but if not there’s other positive news reported.

2)Tests are evaluated in strong robust studies to work out whether they work in the real world for the purposes to which they are put

The above suits us and let’s remember the Affimer is more robust, cheaper to manufacture, more sensitive and can be more quickly developed than its alternatives. I guess the market assumes so to and I assume Mologic will be upfront woth Gates and Soros.

Deeks’ tweet could well be irrelevant. We’ll know tomorrow.

Definitive answer, crack me up! You can’t use PCR testing for mass screening, we haven’t the capacity and results aren’t within mins.

Good to hear Jamie. Did you include -

https://www.sciencemediacentre.org/expert-reaction-to-interim-evaluation-report-from-the-liverpool-covid-19-community-testing-pilot/